BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Yasmeen Rahimi does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 PRTAProthena Corporation plc | Buy | $81.00 | May 2025 | +102.9% | Miss |
 SLNOSoleno Therapeutics Inc | Buy | $145.00 | Apr 2025 | −34.3% | Miss |
 EWTXEdgewise Therapeutics Inc | Buy | $51.00 | Apr 2025 | +141.0% | Miss |
 LXRXLexicon Pharmaceuticals Inc | Buy | $6.00 | Mar 2025 | +367.3% | Miss |
 AVTXAvalo Therapeutics Inc | Buy | $48.00 | Feb 2025 | +160.5% | Miss |
| PRTAProthena Corporation plc | Buy | $110.00 | Feb 2025 | −51.7% | Miss |
 UPBUpstream Bio, Inc. | Buy | $75.00 | Nov 2024 | −9.9% | Miss |
 NKTRNektar Therapeutics | Buy | $7.00 | Nov 2024 | +166.9% | Miss |
| EWTXEdgewise Therapeutics Inc | Buy | $51.00 | Oct 2024 | −47.1% | Miss |
 ZURAZura Bio Limited Class A Ordinary Shares | Buy | $26.00 | Sep 2024 | −45.1% | Miss |
 ALTAltimmune Inc | Buy | $25.00 | Jun 2024 | +6.5% | Miss |
 BNTCBenitec Biopharma Ltd ADR | Buy | $30.00 | Jun 2024 | +130.6% | Miss |
| ZURAZura Bio Limited Class A Ordinary Shares | Buy | $26.00 | May 2024 | −68.6% | Miss |
 UNCYUnicycive Therapeutics Inc | Buy | $9.00 | Apr 2024 | −59.6% | Miss |
 GOSSGossamer Bio Inc | Buy | $15.00 | Mar 2024 | −1.4% | Miss |
 ALGSAligos Therapeutics Inc | Buy | $7.00 | Jan 2023 | −73.9% | Miss |
| ALGSAligos Therapeutics Inc | Buy | $3.00 | Jan 2023 | −50.0% | Miss |
 PRAXPraxis Precision Medicines Inc | Buy | $18.00 | Jun 2022 | −45.9% | Miss |
| ALGSAligos Therapeutics Inc | Buy | $15.00 | Mar 2022 | −44.9% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.